SITC 2022


SGN-BB228 | Preclinical | Abstract #1201

SGN-BB228 is a first-in-class CD228-targeted costimulatory Antibody Anticalin® bispecific delivering potent and conditional 4-1BB costimulation to tumor-specific T cells

SGN-B6A | Solid Tumors | Abstract #731

A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: Interim results of a Phase 1 study (SGNB6A-001)

Enfortumab Vedotin | Preclinical | Abstract #1187

Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors

SGN-B6A | Preclinical | Abstract #1186

SGN-B6A induces immunogenic cell death as a secondary mechanism of action

SGN-B7H4V | Preclinical | Abstract #1190

SGN-B7H4V induces immunomodulatory changes to the tumor microenvironment and pairs well with an anti-PD1 agent in a preclinical model

SEA-CD40 | Advanced Malignancies | Abstract #705

Phase 2 study of SEA-CD40 combination therapies in advanced malignancies (SGNS40-002, trial in progress)

Research | Abstract #1357

Reversible chemical modulation of antibody effector function maintains anti-tumor activity while mitigating peripheral immune activation

Disitimab Vedotin | Urothelial Carcinoma | Abstract #663

Phase 2 multi-cohort clinical study evaluating Disitamab Vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (rc48g001, trial in progress)